Naima Thavory Joseph
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Naima Thavory Joseph has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Melamed
Massachusetts General Hospital, Boston, MA
4 shared publications Donald P. Goldstein
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, USA; Department of Obstetrics, Gynecology & Reproductive Biology, Harvard Medical School Boston, MA, USA; New England Trophoblastic Disease Center, Donald P. Goldstein, MD, Trophoblastic Tumor Registry, Boston, USA; Gynecologic Oncology Program, Susan F. Smith Center for Women's Cancers, Dana Farber Cancer Institute/Harvard Cancer Center, Boston, USA
4 shared publications- Sue Yazaki Sun
Universidade Federal de São Paulo, Brazil
4 shared publications Allison A. Gockley
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, USA; Vincent Department of Obstetrics, Gynecology and Reproductive Biology, Massachusetts General Hospital, Boston, USA; Department of Obstetrics, Gynecology & Reproductive Biology, Harvard Medical School Boston, MA, USA
3 shared publicationsRoss S. Berkowitz
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Boston, USA; Department of Obstetrics, Gynecology & Reproductive Biology, Harvard Medical School Boston, MA, USA; New England Trophoblastic Disease Center, Donald P. Goldstein, MD, Trophoblastic Tumor Registry, Boston, USA; Gynecologic Oncology Program, Susan F. Smith Center for Women's Cancers, Dana Farber Cancer Institute/Harvard Cancer Center, Boston, USA
3 shared publicationsAlona Muzikansky
Department of Biostatistics, Massachusetts General Hospital, Harvard Medical School, Boston, MA
2 shared publications
Latest Publications
- Open Access
- 26 November 2024
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 21 (12) , 1571
Improving the Health and Environmental Health Literacy of Professionals: Evaluating the Effect of a Virtual Intervention on Phthalate Environmental Health Literacy
The American College of Obstetricians and Gynecologists provided updated guidance in 2021, recommending that reproductive health professionals should include discussion of environmental exposures with their patients. However, environmental health is seldom included in medical training, with endocrine-disrupting chemicals, such as phthalates—linked to adverse pregnancy outcomes—being among the least discussed. We developed a one-hour virtual educational intervention to train reproductive health professionals on the routes of phthalate exposure, potential associated health impacts, and suggestions on how to discuss exposure reduction with patients. The intervention was designed to include perspectives from patients, scientists, and clinicians. Using a pre/post/post design, we evaluated the impact of the intervention on reproductive health professionals’ phthalate-related reproductive health literacy via a validated environmental health literacy (EHL) scale, their confidence in discussing phthalates, and the frequency of discussions about phthalates with patients. All materials, including the study questionnaires and intervention materials, were administered virtually to reproductive health professionals (n = 203) currently seeing patients working in the United States. After completing the intervention, reproductive health professionals’ average EHL increased (pre-course: 22.3, post-course: 23.7, 2 months post-course: 24.0), as did their confidence in discussing phthalates with their patients (pre-course: 1% (2/203) reported being quite confident, post-course: 64% (131/203) reported being quite confident, and 2 months post course: 86% (174/203) reported being quite confident). Additionally, the reported frequency of discussions about phthalates with patients rose substantially (pre-course: 0% (0/203) reported usually discussing phthalates with patients, and 2 months post-course: 86% (175/203) reported usually discussing phthalates with patients): In line with the recommendations of the American College of Obstetricians and Gynecologists, this online phthalate educational intervention tool increased EHL among reproductive health professionals and shifted clinical care to include discussion about phthalates, a reproductive toxicant.
- 26 November 2024
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 21 (12) , 1571
Open AccessImproving the Health and Environmental Health Literacy of Professionals: Evaluating the Effect of a Virtual Intervention on Phthalate Environmental Health Literacy
The American College of Obstetricians and Gynecologists provided updated guidance in 2021, recommending that reproductive health professionals should include discussion of environmental exposures with their patients. However, environmental health is seldom included in medical training, with endocrine-disrupting chemicals, such as phthalates—linked to adverse pregnancy outcomes—being among the least discussed. We developed a one-hour virtual educational intervention to train reproductive health professionals on the routes of phthalate exposure, potential associated health impacts, and suggestions on how to discuss exposure reduction with patients. The intervention was designed to include perspectives from patients, scientists, and clinicians. Using a pre/post/post design, we evaluated the impact of the intervention on reproductive health professionals’ phthalate-related reproductive health literacy via a validated environmental health literacy (EHL) scale, their confidence in discussing phthalates, and the frequency of discussions about phthalates with patients. All materials, including the study questionnaires and intervention materials, were administered virtually to reproductive health professionals (n = 203) currently seeing patients working in the United States. After completing the intervention, reproductive health professionals’ average EHL increased (pre-course: 22.3, post-course: 23.7, 2 months post-course: 24.0), as did their confidence in discussing phthalates with their patients (pre-course: 1% (2/203) reported being quite confident, post-course: 64% (131/203) reported being quite confident, and 2 months post course: 86% (174/203) reported being quite confident). Additionally, the reported frequency of discussions about phthalates with patients rose substantially (pre-course: 0% (0/203) reported usually discussing phthalates with patients, and 2 months post-course: 86% (175/203) reported usually discussing phthalates with patients): In line with the recommendations of the American College of Obstetricians and Gynecologists, this online phthalate educational intervention tool increased EHL among reproductive health professionals and shifted clinical care to include discussion about phthalates, a reproductive toxicant.
- 5 July 2024
- Published by Wolters Kluwer Health in Clinical Obstetrics and Gynecology
- Vol. 67 (3) , 555-556
Foreword: Infectious Diseases in Obstetrics
- 5 July 2024
- Published by Wolters Kluwer Health in Clinical Obstetrics and Gynecology
- Vol. 67 (3) , 555-556
Foreword: Infectious Diseases in Obstetrics
- 2 July 2024
- Published by Wolters Kluwer Health in Clinical Obstetrics and Gynecology
- Vol. 67 (3) , 644-651
Updates in the Management of HIV During Pregnancy
Human immunodeficiency virus in pregnant people remains a significant public health issue worldwide. The rate of perinatal transmission is 15% to 40% but can be decreased to less than 1% with appropriate antenatal management. Previous recommendations included a protease inhibitor-based antiretroviral therapy, infant prophylaxis, performance of cesarean section for uncontrolled viremia, and the use of formula for infant feeding. However, recent updates include first line of integrase inhibitor-based regimens and supporting parental choices for safe lactation. In this review, we summarize and provide updated recommendations for the care of people living with human immunodeficiency virus during pregnancy.
- 2 July 2024
- Published by Wolters Kluwer Health in Clinical Obstetrics and Gynecology
- Vol. 67 (3) , 644-651
Updates in the Management of HIV During Pregnancy
Human immunodeficiency virus in pregnant people remains a significant public health issue worldwide. The rate of perinatal transmission is 15% to 40% but can be decreased to less than 1% with appropriate antenatal management. Previous recommendations included a protease inhibitor-based antiretroviral therapy, infant prophylaxis, performance of cesarean section for uncontrolled viremia, and the use of formula for infant feeding. However, recent updates include first line of integrase inhibitor-based regimens and supporting parental choices for safe lactation. In this review, we summarize and provide updated recommendations for the care of people living with human immunodeficiency virus during pregnancy.
- Open Access
- 12 April 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 1-15
The World Health Organization Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns (ACTION-III) Trial: study protocol for a multi-country, multi-centre, double-blind, three-arm, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at high probability of late preterm birth in hospitals in low- resource countries
Background: Preterm birth complications are the leading cause of newborn and under-5 mortality. Over 85% of all preterm births occur in the late preterm period, i.e. between 34 and < 37 weeks of gestation. Antenatal corticosteroids (ACS) prevent mortality and respiratory morbidity when administered to women at high risk of an early preterm birth, i.e. < 34 weeks’ gestation. However, the benefits and risks of ACS in the late preterm period are less clear; both guidelines and practices vary between settings. Emerging evidence suggests that the benefits of ACS may be achievable at lower doses than presently used. This trial aims to determine the efficacy and safety of two ACS regimens compared to placebo, when given to women with a high probability of late preterm birth, in hospitals in low-resource countries. Methods: WHO ACTION III trial is a parallel-group, three-arm, individually randomized, double-blind, placebo-controlled trial of two ACS regimens: dexamethasone phosphate 4 × 6 mg q12h or betamethasone phosphate 4 × 2 mg q 12 h. The trial is being conducted across seven sites in five countries—Bangladesh, India, Kenya, Nigeria, and Pakistan. Eligible women are those with a gestational age between 34 weeks 0 days and 36 weeks 5 days, who have a high probability of preterm birth between 12 h and 7 days (up to 36 weeks 6 days gestation). The primary outcome is a composite of stillbirth or neonatal death within 72 h of birth or use of newborn respiratory support within 72 h of birth or prior to discharge from hospital, whichever is earlier. Secondary outcomes include safety and health utilization measures for both women and newborns. The sample size is 13,500 women. Discussion: This trial will evaluate the benefits and possible harms of ACS when used in women likely to have a late preterm birth. It will also evaluate a lower-dose ACS regimen based on literature from pharmacokinetic studies. The results of this trial will provide robust critical evidence on the safe and appropriate use of ACS in the late preterm period internationally. Trial registration: ISRCTN11434567. Registered on 7 June 2021.
- 12 April 2024
- Published by Springer Nature in Trials
- Vol. 25 (1) , 1-15
Open AccessThe World Health Organization Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns (ACTION-III) Trial: study protocol for a multi-country, multi-centre, double-blind, three-arm, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at high probability of late preterm birth in hospitals in low- resource countries
Background: Preterm birth complications are the leading cause of newborn and under-5 mortality. Over 85% of all preterm births occur in the late preterm period, i.e. between 34 and < 37 weeks of gestation. Antenatal corticosteroids (ACS) prevent mortality and respiratory morbidity when administered to women at high risk of an early preterm birth, i.e. < 34 weeks’ gestation. However, the benefits and risks of ACS in the late preterm period are less clear; both guidelines and practices vary between settings. Emerging evidence suggests that the benefits of ACS may be achievable at lower doses than presently used. This trial aims to determine the efficacy and safety of two ACS regimens compared to placebo, when given to women with a high probability of late preterm birth, in hospitals in low-resource countries. Methods: WHO ACTION III trial is a parallel-group, three-arm, individually randomized, double-blind, placebo-controlled trial of two ACS regimens: dexamethasone phosphate 4 × 6 mg q12h or betamethasone phosphate 4 × 2 mg q 12 h. The trial is being conducted across seven sites in five countries—Bangladesh, India, Kenya, Nigeria, and Pakistan. Eligible women are those with a gestational age between 34 weeks 0 days and 36 weeks 5 days, who have a high probability of preterm birth between 12 h and 7 days (up to 36 weeks 6 days gestation). The primary outcome is a composite of stillbirth or neonatal death within 72 h of birth or use of newborn respiratory support within 72 h of birth or prior to discharge from hospital, whichever is earlier. Secondary outcomes include safety and health utilization measures for both women and newborns. The sample size is 13,500 women. Discussion: This trial will evaluate the benefits and possible harms of ACS when used in women likely to have a late preterm birth. It will also evaluate a lower-dose ACS regimen based on literature from pharmacokinetic studies. The results of this trial will provide robust critical evidence on the safe and appropriate use of ACS in the late preterm period internationally. Trial registration: ISRCTN11434567. Registered on 7 June 2021.
- 6 March 2024
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 67 (1) , 124-128
Pregnancy-Associated Firearm Mortality in the U.S., 2008–2019
- 6 March 2024
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 67 (1) , 124-128
Pregnancy-Associated Firearm Mortality in the U.S., 2008–2019
- 22 February 2023
- Published by Elsevier in Obstetrics and Gynecology Clinics of North America
- Vol. 50 (1) , 183-203
An Overview of Antiviral Treatments in Pregnancy
- 22 February 2023
- Published by Elsevier in Obstetrics and Gynecology Clinics of North America
- Vol. 50 (1) , 183-203
An Overview of Antiviral Treatments in Pregnancy
- 21 October 2022
- Published by Elsevier in Obstetrics and Gynecology Clinics of North America
- Vol. 50 (1) , 163-182
COVID-19 Therapeutics and Considerations for Pregnancy
- 21 October 2022
- Published by Elsevier in Obstetrics and Gynecology Clinics of North America
- Vol. 50 (1) , 163-182
COVID-19 Therapeutics and Considerations for Pregnancy
- Open Access
- 29 June 2022
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 227 (7) , 850-854
Placental Injury and Antibody Transfer after Coronavirus Disease 2019 in Pregnancy
We examined the relationship between placental histopathology and transplacental antibody transfer in pregnant patients after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Differences in plasma concentrations of anti-receptor biding domain (RBD) immunoglobulin (Ig)G antibodies in maternal and cord blood were analyzed according to presence of placental injury. Median anti-RBD IgG concentrations in cord blood with placental injury (n = 7) did not differ significantly from those without injury (n = 16) (median 2.7 [interquartile range {IQR}, 1.8–3.6] vs 2.7 [IQR, 2.4–2.9], P = 0.59). However, they were associated with lower transfer ratios (median 0.77 [IQR, 0.61–0.97] vs 0.97 [IQR, 0.80–1.01], P = 0.05). SARS-CoV-2 placental injury may mediate reduced maternal-fetal antibody transfer.
- 29 June 2022
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 227 (7) , 850-854
Open AccessPlacental Injury and Antibody Transfer after Coronavirus Disease 2019 in Pregnancy
We examined the relationship between placental histopathology and transplacental antibody transfer in pregnant patients after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Differences in plasma concentrations of anti-receptor biding domain (RBD) immunoglobulin (Ig)G antibodies in maternal and cord blood were analyzed according to presence of placental injury. Median anti-RBD IgG concentrations in cord blood with placental injury (n = 7) did not differ significantly from those without injury (n = 16) (median 2.7 [interquartile range {IQR}, 1.8–3.6] vs 2.7 [IQR, 2.4–2.9], P = 0.59). However, they were associated with lower transfer ratios (median 0.77 [IQR, 0.61–0.97] vs 0.97 [IQR, 0.80–1.01], P = 0.05). SARS-CoV-2 placental injury may mediate reduced maternal-fetal antibody transfer.